Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Current lipid-lowering strategies for the treatment of diabetic dyslipidemia: An integrated approach to therapy
Autore:
Marcus, A;
Indirizzi:
S Orange Cty Endocrinol, Laguna Hills, CA 92653 USA S Orange Cty Endocrinol Laguna Hills CA USA 92653 una Hills, CA 92653 USA Univ So Calif, Sch Med, Los Angeles, CA 90089 USA Univ So Calif Los Angeles CA USA 90089 Sch Med, Los Angeles, CA 90089 USA
Titolo Testata:
ENDOCRINOLOGIST
fascicolo: 5, volume: 11, anno: 2001,
pagine: 368 - 383
SICI:
1051-2144(200109/10)11:5<368:CLSFTT>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; INSULIN-DEPENDENT DIABETICS; AVERAGE CHOLESTEROL LEVELS; GEMFIBROZIL COMBINATION THERAPY; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; COMBINED HYPERLIPIDEMIA; SERUM-LIPIDS; HYPERTRIGLYCERIDEMIC PATIENTS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
149
Recensione:
Indirizzi per estratti:
Indirizzo: Marcus, A S Orange Cty Endocrinol, 23961 Calle de la Magdalena,Suite 531, Laguna Hills, CA 92653 USA S Orange Cty Endocrinol 23961 Calle de la Magdalena,Suite 531 Laguna Hills CA USA 92653
Citazione:
A. Marcus, "Current lipid-lowering strategies for the treatment of diabetic dyslipidemia: An integrated approach to therapy", ENDOCRINOLO, 11(5), 2001, pp. 368-383

Abstract

Diabetes mellitus is a metabolic disease that is associated with high rates of cardiovascular mortality. Therapeutic strategies available for treatment of diabetes involve modification of cardiovascular risk factors by dietary changes, tight control of blood glucose, pharmacological lowering of plasma lipids, and reduction of elevated blood pressure. In this review, the role of hypolipidemic agents in treating diabetic patients is addressed. Included are findings from clinical studies that have evaluated the efficacy and safety of various classes of hypolipidemic agents, alone or in combination, in the treatment of diabetic dyslipidemia. Statins are a major class ofhypolipidemic agents that effectively reduce total cholesterol and low-density lipoprotein cholesterol (LDL-C) and plasma triglycerides, while increasing high,density lipoprotein cholesterol (HDL-C) levels. Fibrates are another important class of lipid altering drugs that lower plasma triglycerides, increase HDL C, and favorable modify LDL-C particle composition. Niacin and nicotinic acid analogs lower total cholesterol, LDL C, and triglycerides, while increasing HDL,C. However, niacin therapy may or may not be associated with decreased glucose control. Conventional bile acid sequestrants, although effective in decreasing total cholesterol and LDL-C, can increase triglycerides under certain circum stances. Various combinations of these agents seem to be highly effective at allowing diabetic patients to achieve lipid-lowering goals. Furthers more, new hypolipidemic agents, such as colesevelam hydrochloride, can be used alone or in combination therapy and may offer physicians therapeutic alternatives, particularly for diabetic patientswho cannot tolerate higher dosage levels of systemic agents yet require further reductions to reach plasma cholesterol target levels. Integration of a complete therapeutic strategy targeted to achieve specific reduced levelsof LDL, including effective and safe lipid-lowering drugs for treats ment of dyslipidemia in people with diabetes, will likely reduce the risk and burden of cardiovascular disease in these patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 20:43:20